5-year survival higher for liver cancer due to nonalcoholic fatty liver disease.
ONCOLOGY
Fully funded by 
Content independently selected
-
HCC: NAFLD etiology tied to more surgical complications but better survival -
Breast cancer: T2DM tied to higher odds of TNBC vs ER+/HER2− tumors Risk also elevated with prior metformin use.
-
NSCLC: European consensus report defines oligometastatic disease Experts provide a uniform definition and diagnostic criteria.
-
The draft guidance is open for public consultation until 5 September 2019.
-
ER+ breast cancer: tamoxifen benefit extends 15 years for luminal A subtype Benefit is shorter-lasting for luminal B subtype, as is the risk for distant metastasis.
-
EGFR+ NSCLC: no benefit for bevacizumab with frontline erlotinib Phase 2 study fails to meet primary or secondary survival endpoints.
-
HPV+ head/neck cancer: NCCN monitoring schedule shows limited utility 95% of recurrences were elicited by patient symptoms.
-
Liver cancer: study quantifies annual risk in alcoholic cirrhosis Surveillance is warranted.
-
Smoking tied to risk for renal cancer in meta-analysis Risk rises with smoking intensity and duration.
-
CML-CP: imatinib delivers excellent response with low toxicity in very old patients 7 in 10 patients achieved complete cytogenetic response.
-
Urothelial cancer: enfortumab vedotin active after platinum, anti-PD-1/L1 therapy Favorable phase 2 findings validate Nectin-4 as a therapeutic target.
-
Add-on WBRT extends survival with NSCLC brain metastases Significant benefit achieved by adding whole-brain radiotherapy to EGFR-TKIs.
-
Inflammatory biomarkers predict survival in small-cell esophageal cancer PLR can help identify high-risk patients for more aggressive treatment.
-
Head/neck cancer: small-cell subtype carries poorer prognosis SEER analysis sheds light on this rare malignancy.